A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer

Immune checkpoint inhibitors such as Nivolumab work by preventing the inactivation of host T-cells by tumour cells, thereby allowing the T-cells to attack the tumour cells, which results in tumour tissue necrosis. We describe a 78-year-old woman with metastatic lung adenocarcinoma treated with Nivol...

Descripción completa

Detalles Bibliográficos
Autores principales: Suyanto, Suyanto, Yeo, Daniel, Khan, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421719/
https://www.ncbi.nlm.nih.gov/pubmed/30944744
http://dx.doi.org/10.1155/2019/8356148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421719/
https://www.ncbi.nlm.nih.gov/pubmed/30944744
http://dx.doi.org/10.1155/2019/8356148

Ejemplares similares